MCID: SML019
MIFTS: 56

Smallpox

Categories: Infectious diseases, Rare diseases, Skin diseases

Aliases & Classifications for Smallpox

MalaCards integrated aliases for Smallpox:

Name: Smallpox 12 74 52 54 42 3 43 15 71 32
Ordinary Smallpox 12
Variola 52

Classifications:



External Ids:

Disease Ontology 12 DOID:8736
ICD9CM 34 050 050.9
MeSH 43 D012899
NCIt 49 C35027
SNOMED-CT 67 47452006 67924001
ICD10 32 B03
UMLS 71 C0037354

Summaries for Smallpox

MedlinePlus : 42 Smallpox is a disease caused by the Variola major virus. Some experts say that over the centuries it has killed more people than all other infectious diseases combined. Worldwide immunization stopped the spread of smallpox three decades ago. The last case was reported in 1977. Two research labs still keep small amounts of the virus. Experts fear bioterrorists could use the virus to spread disease. Smallpox spreads very easily from person to person. Symptoms are flu-like. They include High fever Fatigue Headache Backache A rash with flat red sores There is no treatment. Fluids and medicines for pain or fever can help control symptoms. Most people recover, but some can die. Those who do recover may have severe scars. The U.S. stopped routine smallpox vaccinations in 1972. Military and other high-risk groups continue to get the vaccine. The U.S. has increased its supply of the vaccine in recent years. The vaccine makes some people sick, so doctors save it for those at highest risk of disease.

MalaCards based summary : Smallpox, also known as ordinary smallpox, is related to vaccinia and chickenpox, and has symptoms including fever, pruritus and exanthema. An important gene associated with Smallpox is IL2 (Interleukin 2), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Iron-Dextran Complex and Phenol have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and testes, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Disease Ontology : 12 A viral infectious disease that results in infection located in skin, has material basis in Variola virus, which is transmitted by droplets from oral, nasal or pharyngeal mucosa, transmitted by contact with the body fluids, or transmitted by fomites. The infection results in formation of lesions, first on the face, hands and forearms and later on the trunk.

CDC : 3 Before smallpox was eradicated, it was a serious infectious disease caused by the variola virus. It was contagious-meaning, it spread from one person to another. People who had smallpox had a fever and a distinctive, progressive skin rash. Most people with smallpox recovered, but about 3 out of every 10 people with the disease died. Many smallpox survivors have permanent scars over large areas of their body, especially their faces. Some are left blind. Thanks to the success of vaccination, smallpox was eradicated, and no cases of naturally occurring smallpox have happened since 1977. The last natural outbreak of smallpox in the United States occurred in 1949.

Wikipedia : 74 Smallpox was an infectious disease caused by one of two virus variants, Variola major and Variola minor.... more...

Related Diseases for Smallpox

Diseases related to Smallpox via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 539)
# Related Disease Score Top Affiliating Genes
1 vaccinia 33.2 TNF IL2 ICAM1 GZMB CSF2
2 chickenpox 31.7 TNF IL4 IL2 IFNG
3 poliomyelitis 31.6 TNF IL4 IFNG ICAM1
4 encephalitis 31.6 TNF ITIH4 IL1B CXCL9
5 exanthem 31.6 TNF IL2 CSF3 CSF2
6 measles 31.5 TNF IL2 IL1B IFNG
7 typhoid fever 31.4 TNF IL1B IFNG
8 diphtheria 31.3 TNF IL4 IL2 IFNG CSF2
9 viral infectious disease 31.3 TNF ITIH4 IRF1 IL4 IL2 IL1B
10 pericarditis 31.3 TNF IL1B IFNG
11 herpes zoster 31.2 TNF IL2 IFNG
12 tetanus 31.1 TNF IL4 IL2 IL1B IFNG CSF2
13 severe acute respiratory syndrome 31.1 TNF IL2 IFNG CXCL9
14 myocarditis 31.1 TNF IL4 IL2 IL1B IL18 IFNG
15 dermatitis 30.9 TNF IL4 IL2 IL18 IFNG GZMB
16 keratitis, hereditary 30.9 TNF IL1B CXCL9
17 neuritis 30.8 TNF IL4 IL1B IFNG
18 rubella 30.8 TNF IL4 IL2 IL18R1 IFNG
19 stevens-johnson syndrome/toxic epidermal necrolysis 30.7 IL2 IFNG CXCR3
20 mumps 30.7 TNF IRF1 IL2 IL12RB2 IFNG
21 erythema multiforme 30.7 TNF IL4 IL2 IFNG ICAM1 GZMB
22 optic neuritis 30.6 TNF IL1B CXCR3
23 allergic rhinitis 30.6 IL4 IL18 IFNG ICAM1 CSF2
24 rhinitis 30.6 TNF IL4 IFNG ICAM1 CSF2
25 pulmonary tuberculosis 30.6 TNF IL4 IL2 IL18 IFNG
26 tuberculoid leprosy 30.6 IL4 IL2 IFNG
27 brucellosis 30.5 TNF IL4 IL2 IL18 IFNG
28 conjunctivitis 30.5 TNF IL4 IL2 IFNG ICAM1 CXCL9
29 nervous system disease 30.5 TNF IL1B IFNG CXCR3 CSF2
30 severe combined immunodeficiency 30.5 IL4 IL2 IL18R1 IFNG CXCL9 CSF3
31 osteomyelitis 30.5 TNF IL4 IL1B IFNG CSF3
32 gillessen-kaesbach-nishimura syndrome 30.4 IL18BP IL18
33 toxic shock syndrome 30.4 TNF IL4 IL2 IL1B IFNG
34 hepatitis a 30.4 TNF IL4 IL2 IFNG
35 schistosomiasis 30.4 TNF IL4 IL2 IFNG
36 q fever 30.4 TNF IL4 IL1B IFNG CXCL9
37 rheumatic fever 30.4 TNF IL2 IFNG ICAM1
38 pleurisy 30.4 TNF IL2 IFNG ICAM1
39 viral hepatitis 30.4 TNF IL4 IL2 IFNG
40 central nervous system disease 30.4 TNF IL1B IFNG CXCR3
41 dermatitis, atopic 30.4 TNF IL4 IL2 IL1B IL18 IFNG
42 acquired immunodeficiency syndrome 30.3 TNF ITIH4 IL2 IL1B IFNG ICAM1
43 allergic hypersensitivity disease 30.3 TNF IL4 IL2 IFNG ICAM1 CSF2
44 toxoplasmosis 30.3 TNF IL4 IL1B IFNG
45 leprosy 3 30.3 TNF IL4 IL2 IL1B IL12RB2 IFNG
46 stomatitis 30.3 TNF IL4 IL2 IL1B IFNG CSF3
47 skin disease 30.2 TNF IL4 IL2 IL18 IFNG ICAM1
48 graves' disease 30.2 IL4 IFNG ICAM1 CXCR3
49 tonsillitis 30.2 TNF IL4 IL2 IL1B IFNG
50 dilated cardiomyopathy 30.2 TNF IL4 IL2 IL1B IFNG ICAM1

Graphical network of the top 20 diseases related to Smallpox:



Diseases related to Smallpox

Symptoms & Phenotypes for Smallpox

UMLS symptoms related to Smallpox:


fever, pruritus, exanthema

GenomeRNAi Phenotypes related to Smallpox according to GeneCards Suite gene sharing:

26 (show all 29)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.19 IL18
2 Increased shRNA abundance (Z-score > 2) GR00366-A-125 10.19 IL18
3 Increased shRNA abundance (Z-score > 2) GR00366-A-147 10.19 IRF1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.19 IL18
5 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.19 IRF1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-158 10.19 IRF1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-169 10.19 IL18
8 Increased shRNA abundance (Z-score > 2) GR00366-A-173 10.19 IRF1 MTHFR
9 Increased shRNA abundance (Z-score > 2) GR00366-A-180 10.19 IRF1 MTHFR
10 Increased shRNA abundance (Z-score > 2) GR00366-A-182 10.19 IL18
11 Increased shRNA abundance (Z-score > 2) GR00366-A-200 10.19 IRF1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.19 MTHFR
13 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.19 IRF1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-32 10.19 IRF1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-37 10.19 IL18
16 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.19 IL18
17 Increased shRNA abundance (Z-score > 2) GR00366-A-45 10.19 CSF3
18 Increased shRNA abundance (Z-score > 2) GR00366-A-46 10.19 IRF1 MTHFR
19 Increased shRNA abundance (Z-score > 2) GR00366-A-5 10.19 IL18
20 Increased shRNA abundance (Z-score > 2) GR00366-A-54 10.19 IRF1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-6 10.19 CSF3 IL18 IRF1 MTHFR
22 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.19 MTHFR
23 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.19 IL18
24 Increased shRNA abundance (Z-score > 2) GR00366-A-76 10.19 MTHFR
25 Increased shRNA abundance (Z-score > 2) GR00366-A-77 10.19 MTHFR
26 Increased shRNA abundance (Z-score > 2) GR00366-A-83 10.19 CSF3 IRF1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.19 IRF1
28 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.77 GZMA GZMB ICAM1 IL18 IL1B IL2
29 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.77 GZMA GZMB ICAM1 IL18 IL1B IL2

MGI Mouse Phenotypes related to Smallpox:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.24 CSF2 CSF3 CXCR3 GZMA ICAM1 IFNG
2 cardiovascular system MP:0005385 10.17 CSF2 CXCR3 ICAM1 IFNG IL12RB2 IL18
3 homeostasis/metabolism MP:0005376 10.13 CSF2 CXCR3 ICAM1 IFNG IL12RB2 IL18
4 immune system MP:0005387 10.13 CSF2 CSF3 CXCR3 GZMA ICAM1 IFNG
5 endocrine/exocrine gland MP:0005379 10.1 CSF2 ICAM1 IFNG IL12RB2 IL18BP IL2
6 integument MP:0010771 9.85 CSF2 CSF3 ICAM1 IFNG IL18 IL1B
7 liver/biliary system MP:0005370 9.56 IFNG IL12RB2 IL18BP IL2 IL4 ITIH4
8 neoplasm MP:0002006 9.36 CSF2 CXCR3 GZMA ICAM1 IFNG IL12RB2

Drugs & Therapeutics for Smallpox

Drugs for Smallpox (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 50)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Iron-Dextran Complex Phase 3
2
Phenol Approved, Experimental Phase 2 108-95-2 996
3
tannic acid Approved Phase 1, Phase 2 1401-55-4
4
Benzocaine Approved, Investigational Phase 1, Phase 2 1994-09-7, 94-09-7 2337
5
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
6
rituximab Approved Phase 2 174722-31-7 10201696
7 Heptavalent Pneumococcal Conjugate Vaccine Phase 2
8 Vaccines Phase 1, Phase 2
9 Immunologic Factors Phase 2
10 Immunoglobulins Phase 2
11 Antibodies Phase 2
12 Rho(D) Immune Globulin Phase 2
13 Immunoglobulins, Intravenous Phase 2
14 gamma-Globulins Phase 2
15 Antineoplastic Agents, Immunological Phase 2
16 Thymoglobulin Phase 2
17 Isoantibodies Phase 2
18 Antilymphocyte Serum Phase 2
19 Antirheumatic Agents Phase 2
20 Immunosuppressive Agents Phase 2
21
Mannitol Approved, Investigational Phase 1 69-65-8 453 6251
22
Metronidazole Approved Phase 1 443-48-1 4173
23 Pharmaceutical Solutions Phase 1
24 Anti-Bacterial Agents Phase 1
25 Anti-Infective Agents Phase 1
26 Adjuvants, Immunologic Phase 1
27 Keyhole-limpet hemocyanin Phase 1
28 interferons Phase 1
29 Protective Agents Phase 1
30 Antibiotics, Antitubercular Phase 1
31 Antiviral Agents Phase 1
32 polysaccharide-K Phase 1
33 Radiation-Protective Agents Phase 1
34 Interferon Inducers Phase 1
35 Cathartics Phase 1
36 Poly I-C Phase 1
37 Gastrointestinal Agents Phase 1
38 Poly ICLC Phase 1
39 Laxatives Phase 1
40 Carboxymethylcellulose Sodium Phase 1
41 Natriuretic Agents Phase 1
42 diuretics Phase 1
43 Hormone Antagonists Phase 1
44 Hormones Phase 1
45 Androgens Phase 1
46 Antiprotozoal Agents Phase 1
47 Antiparasitic Agents Phase 1
48 Anti-Retroviral Agents Phase 1
49 Interferon-gamma
50 Analgesics, Opioid

Interventional clinical trials:

(show top 50) (show all 107)
# Name Status NCT ID Phase Drugs
1 A Special Access Program for the Prophylactic Vaccination With IMVAMUNE® for Personnel Working Directly With or in the Vicinity of Replicating Vaccinia Virus Completed NCT03472014 Phase 4
2 Vaccinia Vaccination (ACAM2000®) of Plasma Donors for the Production of Vaccinia Immune Globulin Intravenous (VIGIV) Recruiting NCT02443623 Phase 4
3 An Open-label, Single Arm, Phase III Clinical Study to Evaluate the Efficacy and Safety of CJ Smallpox Vaccine in Vaccinia-naive Healthy Volunteers Completed NCT01056770 Phase 3 smallpox vaccine CJ-50300
4 An Open-label, Single Arm, Phase III Clinical Study to Evaluate the Efficacy and Safety of CJ Smallpox Vaccine in Previously Vaccinated Healthy Volunteers Completed NCT01317238 Phase 3 smallpox vaccine CJ-50300
5 Randomized, Double Blind, a Phase II/III Clinical Trial to Evaluate the Efficacy and Safety of CJ-50300 in Healthy Volunteers Completed NCT00607243 Phase 2, Phase 3
6 An Expanded Double-Blind, Placebo Controlled, Multicenter Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti Orthopoxvirus Compound Tecovirimat When Administered Orally for 14 Days in Subjects Completed NCT02474589 Phase 3 tecovirimat
7 Vaccinia Vaccine (ACAM2000) for the Production of Vaccinia Immune Globulin Intravenous (VIGIV) Completed NCT01158157 Phase 3
8 A Randomized, Double-Blind, Placebo-Controlled Phase III Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-Naïve Subjects Completed NCT01144637 Phase 3
9 A Randomized, Open-label Phase III Non-inferiority Trial to Compare Indicators of Efficacy for MVA-BN® Smallpox Vaccine to ACAM2000® in 18-42 Year Old Healthy Vaccinia-naïve Subjects Completed NCT01913353 Phase 3
10 An Open-label, Single Arm Study to Provide Additional Information on Safety and Effectiveness of rVSVΔG-ZEBOV-GP Completed NCT03161366 Phase 3
11 An Open-Label Prospective Cohort Study of IMVAMUNE® Smallpox Vaccine in Adult Healthcare Personnel at Risk for Monkeypox in the Democratic Republic of the Congo Recruiting NCT02977715 Phase 3
12 A Randomized, Double-blind, Multicenter Phase III Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of a Freeze-dried Formulation of MVA-BN® Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects Active, not recruiting NCT03699124 Phase 3
13 A Phase I/II Clinical Trial to Evaluate the Safety and Immunogenicity of LC16m8, A Modified Vaccinia Vaccine, in Healthy Volunteers Unknown status NCT00103584 Phase 1, Phase 2
14 A Multicenter, Double-Blind, Randomized Study of the Safety and Efficacy of Aventis Pasteur's Smallpox Vaccine, USP (APSV) in Vaccinia-Naive Adults. Completed NCT00050518 Phase 2
15 Comparison of Safety and Immunogenicity of a High Dose (5 x 10^8 TCID50) and a Standard Dose (1 x 10^8 TCID50) of IMVAMUNE® in Healthy Vaccinia-Naive Individuals Completed NCT00879762 Phase 2 Placebo
16 Evaluation and Treatment of Ocular Complications of Vaccinia Vaccination: Suitability of NP-016 Vaccinia Immune Globulin (VIG) for Sight-Threatening Conditions [VIG31] Completed NCT00081835 Phase 2 NP-016 Vaccine Immune Globulin (IV-VIG)
17 Comparison of the Safety and Immunogenicity of Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid Formulation IMVAMUNE® (1x10^8 TCID50) Administered by the Subcutaneous Route and a Lower Dose Liquid Formulation IMVAMUNE® (2x10^7 TCID50) Administered by the Intradermal Route in Healthy Vaccinia-Naïve Individuals Completed NCT00914732 Phase 2
18 Take Evaluation and Safety of Smallpox Vaccine (LISTER Strain) in Naïve Healthy Adults. Completed NCT00258947 Phase 2
19 A Multicenter, Open-label Phase I/II Study to Evaluate Safety and Immunogenicity of MVA-BN® Smallpox Vaccine in HIV Infected Subjects (CD4 Counts >350 / µl) and Healthy Subjects With and Without Previous Smallpox Vaccination Completed NCT00189904 Phase 1, Phase 2
20 A Multicenter, Open-label, Controlled Phase II Study to Evaluate Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in 18-40 Year Old Subjects With Diagnosed Atopic Dermatitis Completed NCT00316602 Phase 2
21 A Randomized, Double-blind, Multicenter Phase II Trial to Compare the Immunogenicity and Safety of a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects Completed NCT01668537 Phase 2
22 A Double Blind, Randomized Dose Response Study of Dryvax Vaccine Against Smallpox in Previously Vaccinated Adults Completed NCT00032708 Phase 2
23 Phase II, Double-blind, Randomised, Dose-finding Study to Evaluate the Immunogenicity of Three Different Doses of MVA-BN Smallpox Vaccine in 18-30 Year Old Smallpox naïve Healthy Subjects Completed NCT00189956 Phase 2
24 A Multicenter, Double-Blind, Randomized Dose-Response Study of Dryvax Vaccine Against Smallpox in Previously Unvaccinated Adults Completed NCT00026611 Phase 2
25 A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate Safety and Immunogenicity of One and Two Doses of IMVAMUNE® Smallpox Vaccine in 56-80 Year Old Vaccinia-experienced Subjects Completed NCT00857493 Phase 2
26 Double-Blind, Placebo-Controlled, Dose-Finding, Phase 2 Study Assessing Safety, Tolerability, Immunogenicity of Three Dose Levels of ACAM3000 Modified Vaccinia Ankara Smallpox Vaccine in Adults With and Without Previous Smallpox Vaccination Completed NCT00466245 Phase 2 MVA Smallpox vaccine;Placebo
27 Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine When Increasing the Number of Injections Compared to the Standard Regimen in Immunocompromised Subjects With HIV Infection Completed NCT02038881 Phase 2
28 The Effect of Dose On Safety, Tolerability, and Immunogenicity of ACAM2000 Smallpox Vaccine in Adults Without Previous Smallpox Vaccination Completed NCT00053495 Phase 2
29 A Multicenter, Open-label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA-BN® (IMVAMUNE) Smallpox Vaccine in 18-55 Year Old Naive and Previously Vaccinated HIV Infected Subjects With CD4 Counts >200 - 750/µl. Completed NCT00316589 Phase 2
30 A Partially Randomized, Partially Double-blind, Placebo-controlled Phase II Non-inferiority Study to Evaluate Immunogenicity and Safety of One and Two Doses of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in 18-55 Year Old Healthy Subjects Completed NCT00316524 Phase 2
31 The Effect of Dose on Safety, Tolerability, and Immunogenicity of ACAM2000 Smallpox Vaccine in Adults With Previous Smallpox Vaccination Completed NCT00053482 Phase 2
32 An Open-Label Phase II Study to Evaluate Immunogenicity and Safety of a Single IMVAMUNE Booster Vaccination Two Years After the Last IMVAMUNE Vaccination in Former POX-MVA-005 Vaccinees Completed NCT00686582 Phase 2
33 ACAM 3000 MVA (Acambis Modified Vaccinia Ankara) Immunization Followed by Dryvax® Vaccination of Healthy Vaccinia-Naïve Adults: A Phase I/II, Placebo-Controlled Study of the Effects of Dose and Route of Administration of MVA on Safety, Reactogenicity and Immunogenicity, Followed by Dryvax® Immunization to Assess Effects of MVA Vaccination on Dryvax® Takes Completed NCT00133575 Phase 1, Phase 2
34 A Comparison of Dressing Preparations for Smallpox Vaccination Sites With a Focus Upon the Risk of Secondary Transmission of Vaccinia Virus Completed NCT00063856 Phase 1, Phase 2
35 A Phase I/II Study to Evaluate the Safety and Preliminary Efficacy of Various Concentrations of Aventis Pasteur's Smallpox Vaccine, USP (APSV) in Vaccinia-naive Adults Completed NCT00038987 Phase 1, Phase 2
36 A Multicenter, Double Blind, Randomized Dose-response Study of Dryvax Vaccine Against Smallpox in Previously Vaccinated Adults Completed NCT00050505 Phase 2
37 Evaluation of IMVAMUNE® Smallpox Vaccine With Respect to Safety and Optimization of Immune Responses by Different Vaccination Regimens in Vaccinia-Naïve Adults Completed NCT00437021 Phase 1, Phase 2 Placebo (subcutaneous);Placebo (scarification)
38 A Phase II, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of IMVAMUNE® Using Three Immunization Schedules and Two Modes of Delivery Completed NCT01827371 Phase 2
39 Double-Blind, Randomized, Placebo-Controlled, Multi-Center Trial to Assess Safety, Tolerability, and PK of the Anti-Orthopoxvirus Compound ST-246 When Administered as a Single Daily Oral Dose for 14 Days in Volunteers in the Fed State Completed NCT00907803 Phase 2 ST-246 400 mg;ST-246 600 mg;Placebo
40 Assessment of Protection Against Malaria by Sporozoite Challenge of Healthy Adults Vaccinated With AdCh63 ME-TRAP and MVA ME-TRAP Completed NCT00890760 Phase 1, Phase 2
41 Phase II Trial of a WT-1 Analog Peptide Vaccine in Patients in Complete Remission (CR) From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL) Completed NCT01266083 Phase 2
42 A Study of the Systemic and Cutaneous Immune Responses to Yellow Fever Vaccination in Atopic Dermatitis Subjects Completed NCT00723489 Phase 1, Phase 2 YFV-17D Placebo
43 A Randomized Phase II Study of a PSA-Based Vaccine in Patients With Localized Prostate Cancer Receiving Standard Radiotherapy Completed NCT00005916 Phase 2 rV-PSA;rF-PSA;rV-B7.1
44 A Phase II Study Evaluating the Safety and Immunogenicity of a New TB Vaccine, MVA85A, in Healthy Children and Infants After BCG Vaccination at Birth Completed NCT00679159 Phase 2
45 Open Label, Dose Escalation and Age De-escalation for ChAdOx1 85A in Ugandan Adults and Adolescents, Followed by a Phase IIa Randomised, Open-label Trial Among Adolescents Comparing ChAdOx1 85A Prime Followed by MVA 85A Boost Versus BCG Re-vaccination. Recruiting NCT03681860 Phase 1, Phase 2
46 The Effect of Dose On Safety, Tolerability, and Immunogenicity of ACAM1000 Smallpox Vaccine in Adults Without Previous Smallpox Vaccination A Phase 2, Randomized, Double-Blind, Dose-Response Study Terminated NCT00053508 Phase 2
47 Multi-Drug Desensitization Protocol for Heart Transplant Candidates Terminated NCT01556347 Phase 2 Bortezomib, Thymoglobulin, Rituximab, Gamimune N, (IVIG), Plasmapheresis
48 The Safety, Tolerability, and Immunogenicity of Three Dose Levels of ACAM3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine, in Adults Without Previous Smallpox Vaccination Completed NCT00079820 Phase 1
49 A Phase I/II Clinical Trial of Modified Vaccinia Virus Ankara (MVA) to Evaluate Its Safety, Immunogenicity and Protective Efficacy Against Dryvax® (Registered Trademark) Challenge in Vaccinia-Immune Individuals Completed NCT00053742 Phase 1 Modified Vaccinia Virus Ankara TBC-MVA
50 MVA-BN (IMVAMUNE®) Immunization in Persons Who Have Undergone Prior Hematopoietic Stem Cell Transplant (HSCT): A Phase I, Placebo-Controlled Study of the Safety, Reactogenicity and Immunogenicity of MVA Immunization Completed NCT00565929 Phase 1 Placebo

Search NIH Clinical Center for Smallpox

Cochrane evidence based reviews: smallpox

Genetic Tests for Smallpox

Anatomical Context for Smallpox

MalaCards organs/tissues related to Smallpox:

40
Skin, T Cells, Testes, Bone, Kidney, Prostate, Myeloid

Publications for Smallpox

Articles related to Smallpox:

(show top 50) (show all 7491)
# Title Authors PMID Year
1
Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox. 61 42
31722150 2019
2
Estimating the medical capacity required to administer mass prophylaxis: a hypothetical outbreak of smallpox virus infection in Korea. 61 42
31623421 2019
3
On the "Take" as a Biomarker. 42
31722158 2019
4
Structural basis for antagonism of human interleukin 18 by poxvirus interleukin 18-binding protein. 54 61
19104048 2008
5
Yaba monkey tumor virus encodes a functional inhibitor of interleukin-18. 54 61
17959666 2008
6
Macrophage inflammatory protein 3alpha deficiency in atopic dermatitis skin and role in innate immune response to vaccinia virus. 54 61
17141855 2007
7
Variola virus IL-18 binding protein interacts with three human IL-18 residues that are part of a binding site for human IL-18 receptor alpha subunit. 54 61
16979683 2007
8
Structure of vaccinia virus thymidine kinase in complex with dTTP: insights for drug design. 54 61
17062140 2006
9
Accurate mass precursor ion data and tandem mass spectrometry identify a class I human leukocyte antigen A*0201-presented peptide originating from vaccinia virus. 54 61
16185891 2005
10
Evolutionary history of orthopoxvirus proteins similar to human complement regulators. 54 61
16023794 2005
11
Identification of residues in an orthopoxvirus interleukin-18 binding protein involved in ligand binding and species specificity. 54 61
15193916 2004
12
Identification of the canarypox virus thymidine kinase gene and insertion of foreign genes. 54 61
10191193 1999
13
WHO celebrates 40 years since eradication of smallpox. 61
32006510 2020
14
Evidence of vaccinia dissemination despite lack of major reaction following smallpox vaccination. 61
31899026 2020
15
Repair of a previously uncharacterized second host-range gene contributes to full replication of modified vaccinia virus Ankara (MVA) in human cells. 61
32019881 2020
16
Erythema multiforme, Stevens Johnson syndrome, and toxic epidermal necrolysis reported after vaccination, 1999-2017. 61
31870573 2020
17
Re-assessing the Foundations: Worldwide Smallpox Eradication, 1957-67. 61
31933503 2020
18
Drug development against smallpox: present and future. 61
31932370 2020
19
Smallpox in the Post-Eradication Era. 61
31991671 2020
20
Use of live Variola virus to determine whether CAST/EiJ mice are a suitable surrogate animal model for human smallpox. 61
31593747 2020
21
An Analysis of the United States and United Kingdom Smallpox Epidemics (1901-5) - The Special Relationship that Tested Public Health Strategies for Disease Control. 61
31933500 2020
22
Co-administration of tecovirimat and ACAM2000™ in non-human primates: Effect of tecovirimat treatment on ACAM2000 immunogenicity and efficacy versus lethal monkeypox virus challenge. 61
31677948 2020
23
What Should Health Science Journalists Do in Epidemic Responses? 61
31958392 2020
24
Stopping live vaccines after disease eradication may increase mortality. 61
31648913 2020
25
The Falconi's needle against anti-vaccination: A minimally invasive tool in the nineteenth century. 61
31928854 2020
26
Asymptomatic Orthopoxvirus Circulation in Humans in the Wake of a Monkeypox Outbreak among Chimpanzees in Cameroon. 61
31769389 2020
27
Antibiotics: From the Beginning to the Future: Part 1. 61
31713213 2020
28
The Prevention of Infections in Older Adults: Vaccination. 61
31613000 2020
29
Humanized Mice for Live-Attenuated Vaccine Research: From Unmet Potential to New Promises. 61
31973073 2020
30
Is there an association between Stevens-Johnson Syndrome and vaccination? A systematic review. 61
31713580 2020
31
High risk genotypes for schizophrenia may have been adaptive in the context of smallpox. 61
31935637 2020
32
What a Difference a Gene Makes: Identification of Virulence Factors of Cowpox Virus. 61
31645446 2020
33
Extended sequencing of vaccine and wild-type capripoxvirus isolates provides insights into genes modulating virulence and host range. 61
31379093 2020
34
Evidence for Residual Immunity to Smallpox After Vaccination and Implications for Re-emergence. 61
31369103 2019
35
Evidence of Long-Distance Aerial Convection of Variola Virus and Implications for Disease Control. 61
31892158 2019
36
Seroprevalence and Risk Factors Possibly Associated with Emerging Zoonotic Vaccinia Virus in a Farming Community, Colombia. 61
31743085 2019
37
Human Monkeypox: Epidemiologic and Clinical Characteristics, Diagnosis, and Prevention. 61
30981594 2019
38
Developing the concept of beneficial non-specific effect of live vaccines with epidemiological studies. 61
31449870 2019
39
Finding a way to address a wicked problem: vaccines, vaccination, and a shared understanding. 61
31799892 2019
40
Loss of Pre-Existing Immunological Memory among HIV Infected Women Despite Immune Reconstitution with Antiretroviral Therapy. 61
31867597 2019
41
Loss of resistance to mousepox during chronic lymphocytic choriomeningitis virus infection is associated with impaired T-cell responses and can be rescued by immunization. 61
31826990 2019
42
Screening and evaluation of potential inhibitors against vaccinia virus from 767 approved drugs. 61
31294846 2019
43
Preemptive Tecovirimat Use in an Active Duty Service Member Who Presented With Acute Myeloid Leukemia After Smallpox Vaccination. 61
30959520 2019
44
Post-Exposure Effects of Vaccines on Infectious Diseases. 61
31680134 2019
45
Kinetic Study of DNA Topoisomerases by Supercoiling-Dependent Fluorescence Quenching. 61
31720544 2019
46
Profiling of the antibody response to attenuated LC16m8 smallpox vaccine using protein array analysis. 61
31540810 2019
47
Novel Treatment of a Vaccinia Virus Infection from an Occupational Needlestick - San Diego, California, 2019. 61
31647789 2019
48
Design of inhibitors of thymidylate kinase from Variola virus as new selective drugs against smallpox: part II. 61
30488769 2019
49
Smallpox and BCG vaccination in childhood and cutaneous malignant melanoma in Danish adults followed from 18 to 49 years. 61
31537447 2019
50
Phase-out of smallpox vaccination and the female/male HIV-1 prevalence ratio: an ecological study from Guinea-Bissau. 61
31666269 2019

Variations for Smallpox

Expression for Smallpox

Search GEO for disease gene expression data for Smallpox.

Pathways for Smallpox

Pathways related to Smallpox according to GeneCards Suite gene sharing:

(show top 50) (show all 77)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.12 TNF IRF1 IL4 IL2 IL1B IL18R1
2
Show member pathways
13.92 TNF IL4 IL2 IL1B IL18R1 IL18
3
Show member pathways
13.79 TNF IL4 IL2 IL1B IL18R1 IL18
4
Show member pathways
13.64 TNF IRF1 IL4 IL2 IL1B IL18R1
5
Show member pathways
13.5 TNF IL4 IL2 IL1B IL18R1 IL18
6
Show member pathways
13.38 TNF IL4 IL2 IL1B IL18R1 IL18
7
Show member pathways
13.29 TNF IRF1 IL4 IL2 IL1B IL18R1
8
Show member pathways
13.16 TNF IL2 IL1B IL18 IFNG CXCL9
9
Show member pathways
12.97 TNF IL4 IL2 IL1B IFNG ICAM1
10
Show member pathways
12.91 TNF IL2 IL1B IL18 IFNG ICAM1
11
Show member pathways
12.81 TNF IRF1 IL1B IL18 IFNG
12
Show member pathways
12.78 TNF IL4 IL2 IL18R1 IL18 IL12RB2
13
Show member pathways
12.74 TNF IL2 IL1B IL18R1 IL18 IFNG
14
Show member pathways
12.72 TNF IL4 IL2 IL1B IFNG CSF2
15
Show member pathways
12.71 TNF IL4 IL2 IL1B IL18R1 IL18
16
Show member pathways
12.64 TNF IL4 IL2 IFNG ICAM1 GZMB
17 12.64 TNF IRF1 IL4 IL2 IL1B IFNG
18
Show member pathways
12.49 TNF IL4 IL1B IFNG CSF3 CSF2
19
Show member pathways
12.48 TNF IL2 IL18R1 IL18 CXCR3 CXCL9
20
Show member pathways
12.48 IL4 IL2 IL12RB2 IFNG CSF3 CSF2
21
Show member pathways
12.46 TNF MTHFR IL4 IL2 IL1B IFNG
22 12.42 TNF IL1B IL18 CSF2
23
Show member pathways
12.42 TNF IRF1 IL4 IL2 IL1B IL18
24 12.39 TNF IL2 ICAM1 CSF2
25
Show member pathways
12.37 TNF IRF1 IL1B IL18R1 IL18BP IL18
26
Show member pathways
12.35 TNF IRF1 IL1B IFNG
27
Show member pathways
12.32 TNF IL4 IL1B IFNG
28
Show member pathways
12.32 TNF IRF1 IL4 IL1B IFNG
29 12.29 TNF IL1B IL18 IFNG
30
Show member pathways
12.28 TNF IRF1 IL2 IL1B
31
Show member pathways
12.19 TNF IL4 IL1B IFNG CSF2
32 12.17 TNF IL1B IFNG ICAM1
33 12.16 TNF IL4 IL2 IL1B IFNG ICAM1
34 12.14 TNF IL4 IL1B IL18 ICAM1
35 12.14 TNF IL4 IL2 IFNG CSF3 CSF2
36 12.12 TNF IRF1 IL1B IL18R1 ICAM1 CSF2
37 12.11 TNF IL2 IL1B IL18
38
Show member pathways
12.09 TNF IL2 IL1B IL18R1 IL18 IL12RB2
39 12.07 TNF IL4 IL1B CSF3 CSF2
40 12.03 TNF IL1B IFNG CSF2
41 11.98 TNF IL1B IL18 IFNG ICAM1 CSF2
42
Show member pathways
11.92 IRF1 IL1B IFNG
43 11.92 IL1B IL18 IFNG CSF2
44
Show member pathways
11.92 TNF IL4 IL2 IFNG CSF2
45 11.9 TNF IL2 IL1B IFNG CSF2
46 11.89 IRF1 IL4 IL2 IFNG ICAM1 CSF2
47 11.81 TNF IRF1 IL1B
48 11.81 TNF IL4 IL1B CSF3 CSF2
49
Show member pathways
11.78 TNF IL2 IFNG GZMB
50 11.74 IRF1 IL2 IFNG

GO Terms for Smallpox

Cellular components related to Smallpox according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.73 TNF ITIH4 IL4 IL2 IL1B IL18BP
2 external side of plasma membrane GO:0009897 9.65 TNF IL12RB2 ICAM1 CXCR3 CXCL9
3 extracellular space GO:0005615 9.36 TNF IL4 IL2 IL1B IL18BP IL18
4 immunological synapse GO:0001772 9.33 ICAM1 GZMB GZMA

Biological processes related to Smallpox according to GeneCards Suite gene sharing:

(show top 50) (show all 52)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.23 TNF IRF1 IL4 IL2 IL1B IL18
2 apoptotic process GO:0006915 10.15 IRF1 IL1B IFNG GZMB GZMA CXCR3
3 positive regulation of cell proliferation GO:0008284 10.09 IL2 IL1B IL12RB2 IFNG CSF3 CSF2
4 positive regulation of gene expression GO:0010628 10.06 TNF IL4 IL1B IL18 IFNG CSF2
5 inflammatory response GO:0006954 10.03 TNF IL1B IL18R1 IL18 CXCR3 CXCL9
6 cell-cell signaling GO:0007267 10 IL2 IL1B IL18 CXCL9
7 MAPK cascade GO:0000165 10 TNF IL2 IL1B IL18 CSF2
8 positive regulation of protein phosphorylation GO:0001934 9.97 TNF IL2 IL1B IFNG
9 response to lipopolysaccharide GO:0032496 9.96 IL1B IL18BP IL12RB2 ICAM1
10 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.89 TNF IL18 CSF3
11 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.89 TNF IL1B IL18R1 IL18 ICAM1
12 interferon-gamma-mediated signaling pathway GO:0060333 9.87 IRF1 IFNG ICAM1
13 cellular response to organic cyclic compound GO:0071407 9.87 TNF IL1B IL18
14 positive regulation of inflammatory response GO:0050729 9.87 TNF IL2 IL1B IL18
15 regulation of insulin secretion GO:0050796 9.86 TNF IL1B IFNG
16 positive regulation of T cell proliferation GO:0042102 9.86 IL4 IL2 IL1B
17 cellular response to cytokine stimulus GO:0071345 9.85 IL18R1 IL18BP CSF3
18 cellular response to lipopolysaccharide GO:0071222 9.85 TNF IL1B ICAM1 CXCL9 CSF3 CSF2
19 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.83 TNF IL1B IL18R1 IL18
20 positive regulation of phagocytosis GO:0050766 9.81 TNF IL1B IFNG
21 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.8 TNF IL1B CSF2
22 lipopolysaccharide-mediated signaling pathway GO:0031663 9.79 TNF IL1B IL18
23 positive regulation of nitric oxide biosynthetic process GO:0045429 9.76 TNF IL1B IFNG ICAM1
24 natural killer cell activation GO:0030101 9.75 IL2 IL18R1 IL18
25 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.73 TNF IL4 IL2 IL18 IFNG CSF2
26 astrocyte activation GO:0048143 9.72 TNF IL1B IFNG
27 positive regulation of podosome assembly GO:0071803 9.71 TNF CSF2
28 positive regulation of granulocyte macrophage colony-stimulating factor production GO:0032725 9.71 IL1B IL18
29 negative regulation of amyloid-beta clearance GO:1900222 9.71 TNF IFNG
30 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.71 TNF IL1B IFNG
31 positive regulation of isotype switching to IgG isotypes GO:0048304 9.7 IL4 IL2
32 positive regulation of MHC class II biosynthetic process GO:0045348 9.7 IL4 IFNG
33 T-helper 1 type immune response GO:0042088 9.7 IL18BP IL18
34 positive regulation of neuroinflammatory response GO:0150078 9.69 TNF IL1B IL18
35 regulation of establishment of endothelial barrier GO:1903140 9.68 TNF IL1B
36 interleukin-6 production GO:0032635 9.67 IL1B IL18
37 positive regulation of tissue remodeling GO:0034105 9.66 IL2 IL18
38 neuroinflammatory response GO:0150076 9.65 IL4 IFNG
39 type 2 immune response GO:0042092 9.65 IL4 IL18
40 positive regulation of interleukin-23 production GO:0032747 9.65 IFNG CSF2
41 positive regulation of chemokine biosynthetic process GO:0045080 9.65 TNF IL1B IFNG
42 positive regulation of fever generation GO:0031622 9.64 TNF IL1B
43 positive regulation of cellular respiration GO:1901857 9.63 IL4 IFNG
44 sequestering of triglyceride GO:0030730 9.63 TNF IL1B
45 positive regulation of interferon-gamma production GO:0032729 9.63 TNF IL2 IL1B IL18R1 IL18 IL12RB2
46 interleukin-18-mediated signaling pathway GO:0035655 9.61 IL18R1 IL18BP IL18
47 cytokine-mediated signaling pathway GO:0019221 9.61 TNF IL4 IL2 IL1B IL18 IL12RB2
48 positive regulation of vitamin D biosynthetic process GO:0060557 9.6 TNF IFNG
49 positive regulation of nitrogen compound metabolic process GO:0051173 9.59 TNF IFNG
50 positive regulation of T-helper 1 cell cytokine production GO:2000556 9.58 IL1B IL18R1 IL18

Molecular functions related to Smallpox according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.46 IL4 IL2 CSF3 CSF2
2 cytokine activity GO:0005125 9.28 TNF IL4 IL2 IL1B IL18 IFNG
3 interleukin-18 binding GO:0042007 8.96 IL18R1 IL18BP

Sources for Smallpox

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....